CV, renal and metabolic comorbidities are common. Up to 47% of heart failure patients are living with diabetes. Diabetes accounts for up to 50% of end-stage renal disease cases.

More than 30 million Americans have diabetes and another 84.1 million adults are at risk for developing it.

- CV disease is the number one cause of death in the US.
- Adults with diabetes are twice as likely than those without diabetes to have heart disease or stroke.
- CV disease is the number one cause of death in the US.

Did You Know?

- Science is uncovering commonalities between CV, renal, and metabolic disease, explaining why the idea of reducing CV risk is so complex.
- We are using this knowledge to redefine the way these diseases are understood and how patients are treated, and to ultimately identify new approaches to permanently reduce CV risk.
- Ultimately, we are looking to not just slow CV-related disease, but also to modify or even halt the natural course of the disease and regenerate organs.
- We initiate programs that help to advance patient community health and promote public awareness of cardiovascular health issues.

Our Commitment to Advancing Patient and Community Health

Spotlight on:
CARDIOVASCULAR AND METABOLIC DISEASE (CVMD)

1. Increase awareness of the overlap that exists between cardiovascular (CV), renal and metabolic diseases
   - Science is uncovering commonalities between CV, renal, and metabolic disease, explaining why the idea of reducing CV risk is so complex.
   - We are using this knowledge to redefine the way these diseases are understood and how patients are treated, and to ultimately identify new approaches to permanently reduce CV risk. Ultimately, we are looking to not just slow CV-related disease, but also to modify or even halt the natural course of the disease and regenerate organs.
   - We initiate programs that help to advance patient community health and promote public awareness of cardiovascular health issues.

2. Ensure access to CVMD care for all those who need it
   - AstraZeneca’s goal is to provide affordable access to our products. We are committed to developing and maintaining access and affordability programs for our medicines.
   - AZ&Me: AstraZeneca has a long history of helping qualified patients afford the medicines they need through our patient assistance programs. We have one of the longest standing patient assistance programs in the industry, which provides eligible patients with AstraZeneca medicines at no cost. Over the past 10 years, the AZ&Me Prescription Savings Program has provided prescription savings to more than 4.5 million patients in the United States and Puerto Rico.
   - AstraZeneca Access 360: After our medicines have been prescribed, we provide commercially insured patients and healthcare providers with reimbursement support for our medicines and connections to affordability programs through our AstraZeneca Access 360 program.
   - Copay Savings Programs: We offer copay savings programs to help eligible, commercially insured patients reduce copay costs, and we are exploring ways to further assist patients with affordability in partnership with payers.
   - Medicare Part D: For Medicare Part D, we provide a 50% discount in the coverage gap, where out-of-pocket costs are higher under the design of the program. This discount is provided on top of the rebates provided to Medicare Part D plans as the result of robust negotiations despite any guarantee that the full value of these rebates will be passed along to patients.
   - AstraZeneca is committed to pursuing innovative collaborations with providers, insurers, and health systems toward our shared goal of improving patient health by advancing quality of care, establishing meaningful patient access, and lowering the total cost of care.

3. Advance the standard of CVMD care
   - At AstraZeneca, we advocate for policies that improve access to treatment, increase adherence to medicines, and reduce hospital stays and readmissions for patients.
   - Wherever possible, we also look for ways to make connections across CV and diabetes organizations in pursuit of shared solutions to the complexities of comorbid patient care. We continue to strengthen our commitment to following the science and putting patients first through strategic partnerships, collaborations, and new clinical studies.
   - We support annually more than 20 organizations with a combined reach of more than 1.2 million patients and healthcare professionals.
   - In addition to larger-scale initiatives, we work every day with advocates across the CVMD community with the common goal of improving the care of patients through dialogue and collaboration.

To learn more about our corporate responsibility commitment to advancing patient and community health beyond the medicine, visit: https://www.astrazeneca-us.com/sustainability.html